$ATEX

Lang Scott A. sold $3.2M of ATEX

Lang Scott A. (President and CEO) sold 35,057 shares of Anterix Inc. (ATEX) at an average of $90.22 ($88.96–$91.69, $3.16M total) across 4 trades on 2026-08-14.

Original reporting
SEC EDGAR · Lang Scott A.
Published Aug 17, 2026, 9:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 17, 2026, 9:10 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ATEX
Neutral
medium confidence
Mentioned
$ATEX
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ATEXNeutralLow
01

Why it matters

Traders may reassess short-term sentiment around ATEX due to the CEO’s $3.16M sale, but there is no accompanying fundamental catalyst in the text.

02

Market read

A CEO insider sale at roughly $90/share is newly disclosed, but the filing contains no guidance, deal, or operational update.

03

What to watch

The text notes no pre-arranged 10b5-1 plan, which can amplify interpretation risk; however, the filing does not provide motive, tax context, or whether sales were part of a broader compensation schedule.

Relevance 6/10Novelty 5/10Timing: filed after-hours on 2026-08-17, reflecting trades dated 2026-08-14

Background

The article is a SEC Form 4 insider transaction disclosure for Anterix Inc. (ATEX), listing CEO Lang Scott’s open-market sales.

Company-level read

Ticker impact

$ATEXNeutralMedium confidence
Context

Anterix CEO Lang Scott sold about $3.16M of ATEX shares in open-market trades at roughly $88.96 to $91.69 per share.

Expected impact

Near-term sentiment impact is likely limited; any reaction would be more about optics than new company-specific fundamentals.

Evidence & confidence

This is a Form 4 insider transaction with disclosed sale size and price range, but it provides no new guidance, contracts, or operational updates. The absence of a stated 10b5-1 plan in the text can increase attention, yet insider sales are often routine.

Market effects

Limited sector read-through; insider-sale optics typically do not reset sector expectations without accompanying operational news.

No clear regional spillover indicated by the filing alone.

No global market linkage beyond company-specific sentiment.

Counterpoint

The CEO sale could be planned for liquidity or diversification and may not signal reduced confidence, especially given multi-trade execution over a narrow price band.

Key entities

  • Anterix Inc.

    Public company whose CEO insider sale is disclosed via Form 4.

  • Lang Scott A.

    President and CEO who sold 35,057 ATEX shares across four trades.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ATEXMed

Is Anterix (ATEX) Quietly Reframing Its Connectivity Moat With New 900 MHz FCC Flexibility?

Anterix (ATEX) gained attention after the FCC approved expanded 900 MHz broadband use and granted it a license for satellite testing. This could broaden its network applications and reinforce its investment narrative, though profitability currently relies heavily on noncash spectrum gains. Analysts project $6.9M revenue and $935K earnings by 2028, with a potential 36% downside from current prices.

$ATEXMed

Anterix (ATEX) Q1 2027 Earnings Call Transcript

Anterix (ATEX) reported Q1 2027 revenue of $2M, up from $1.4M YoY, with net income of $240K. Operating expenses decreased to $12.9M. The company has $116M in cash, no debt, and $226.7M left for share repurchases. Management highlighted 12 active deals, spectrum clearing progress, and support for SpaceX's FCC proposal. CFO warned of potential higher costs if spectrum clearing is accelerated.

$ATEXMed

Anterix Inc. (ATEX): Results of Operations and Financial Condition

Anterix Inc. (ATEX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Anterix Inc. Reports First Quarter Fiscal Year 2027 Results Woodland Park, NJ – August 11, 2026 – Anterix (NASDAQ: ATEX) today announced its first quarter fiscal 2027 results and filed its Form 10-Q for the three months ended June 30, 2026. Financial and Operational Highlights –

$ATEXMed

Anterix Inc. (ATEX): Results of Operations and Financial Condition

Anterix Inc. (ATEX) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 atex-20260331xpressrelease.htm EX-99.1 Document Anterix Inc. Reports Full Fiscal Year 2026 Results Woodland Park, NJ – June 10, 2026 – Anterix (NASDAQ: ATEX) today announced fiscal 2026 fourth quarter and full fiscal year financial results for the year ended March 31, 2